NASDAQ:XLRN - Acceleron Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $40.99 -0.93 (-2.22 %) (As of 01/21/2019 02:33 PM ET)Previous Close$41.92Today's Range$40.85 - $42.7252-Week Range$32.53 - $59.59Volume613,271 shsAverage Volume586,044 shsMarket Capitalization$1.89 billionP/E Ratio-15.29Dividend YieldN/ABeta1.39 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts. Receive XLRN News and Ratings via Email Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XLRN Previous Symbol CUSIPN/A Webwww.acceleronpharma.com Phone617-649-9200Debt Debt-to-Equity RatioN/A Current Ratio21.68 Quick Ratio21.68Price-To-Earnings Trailing P/E Ratio-15.29 Forward P/E Ratio-16.33 P/E GrowthN/A Sales & Book Value Annual Sales$13.48 million Price / Sales140.45 Cash FlowN/A Price / Cash FlowN/A Book Value$8.07 per share Price / Book5.08Profitability EPS (Most Recent Fiscal Year)($2.68) Net Income$-108,450,000.00 Net Margins-807.36% Return on Equity-32.69% Return on Assets-30.94%Miscellaneous Employees139 Outstanding Shares46,190,000Market Cap$1.89 billion OptionableOptionable Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions What is Acceleron Pharma's stock symbol? Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN." How were Acceleron Pharma's earnings last quarter? Acceleron Pharma Inc (NASDAQ:XLRN) released its quarterly earnings data on Tuesday, October, 30th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.66) by $0.03. The biopharmaceutical company had revenue of $3.30 million for the quarter, compared to the consensus estimate of $4.37 million. Acceleron Pharma had a negative return on equity of 32.69% and a negative net margin of 807.36%. The company's quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.65) earnings per share. View Acceleron Pharma's Earnings History. When is Acceleron Pharma's next earnings date? Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Acceleron Pharma. What price target have analysts set for XLRN? 10 Wall Street analysts have issued 1 year target prices for Acceleron Pharma's shares. Their predictions range from $33.00 to $75.00. On average, they expect Acceleron Pharma's stock price to reach $56.20 in the next year. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for Acceleron Pharma. What is the consensus analysts' recommendation for Acceleron Pharma? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma. Has Acceleron Pharma been receiving favorable news coverage? News coverage about XLRN stock has been trending positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acceleron Pharma earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. Who are some of Acceleron Pharma's key competitors? Some companies that are related to Acceleron Pharma include bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Atara Biotherapeutics (ATRA), Regenxbio (RGNX) and Editas Medicine (EDIT). Who are Acceleron Pharma's key executives? Acceleron Pharma's management team includes the folowing people: Mr. Habib J. Dable, CEO, Pres & Director (Age 50)Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)Mr. Kevin F. McLaughlin, CFO, Sr. VP & Treasurer (Age 63)Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48) How do I buy shares of Acceleron Pharma? Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Acceleron Pharma's stock price today? One share of XLRN stock can currently be purchased for approximately $40.99. How big of a company is Acceleron Pharma? Acceleron Pharma has a market capitalization of $1.89 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe. What is Acceleron Pharma's official website? The official website for Acceleron Pharma is http://www.acceleronpharma.com. How can I contact Acceleron Pharma? Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected] MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 400 (Vote Outperform)Underperform Votes: 260 (Vote Underperform)Total Votes: 660MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: What is net income?